Brolucizumab - Latest Advances

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Journal: BMJ open

Published: October 08, 2025

Litigation Involving Intravitreal Injections in Ophthalmology: A Review of Legal Claims and Outcomes.

Journal: Ophthalmology. Retina

Published: September 25, 2025

Modified pro re nata regimen of brolucizumab in treatment-naive neovascular age-related macular degeneration.

Journal: Retinal cases & brief reports

Published: September 10, 2025

Evaluation of Intraocular Anti-vascular Endothelial Growth Factor (VEGF) Drug-Associated Adverse Events Using Spontaneous Reporting Databases.

Journal: Cureus

Published: August 31, 2025

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study.

Journal: Journal of clinical medicine

Published: August 20, 2025

Anti-vascular endothelial growth factor therapies in ophthalmology.

Journal: Medical hypothesis, discovery & innovation ophthalmology journal

Published: August 11, 2025

Evidence-Based Guidelines for Intravitreal Anti-VEGF Therapy for Diabetic Retinopathy in Chronic Kidney Disease.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: July 29, 2025

Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China.

Journal: BMJ open

Published: July 28, 2025

Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis.

Journal: American journal of ophthalmology

Published: July 03, 2025

Sterile Intraocular Inflammation Following Intravitreal Injections: Pathogenesis, Clinical Features, and Management.

Journal: International ophthalmology clinics

Published: July 02, 2025

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: June 29, 2025

Comparison of ocular blood flow changes at 30 minutes after intravitreal injection of faricimab, brolucizumab, and aflibercept 2 mg for neovascular age-related macular degeneration.

Journal: Retina (Philadelphia, Pa.)

Published: June 27, 2025

Filters

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches.

Litigation Involving Intravitreal Injections in Ophthalmology: A Review of Legal Claims and Outcomes.

Litigation Involving Intravitreal Injections in Ophthalmology: A Review of Legal Claims and Outcomes.

Modified pro re nata regimen of brolucizumab in treatment-naive neovascular age-related macular degeneration.

Modified pro re nata regimen of brolucizumab in treatment-naive neovascular age-related macular degeneration.

Evaluation of Intraocular Anti-vascular Endothelial Growth Factor (VEGF) Drug-Associated Adverse Events Using Spontaneous Reporting Databases.

Evaluation of Intraocular Anti-vascular Endothelial Growth Factor (VEGF) Drug-Associated Adverse Events Using Spontaneous Reporting Databases.

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study.

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study.

Anti-vascular endothelial growth factor therapies in ophthalmology.

Anti-vascular endothelial growth factor therapies in ophthalmology.

Evidence-Based Guidelines for Intravitreal Anti-VEGF Therapy for Diabetic Retinopathy in Chronic Kidney Disease.

Evidence-Based Guidelines for Intravitreal Anti-VEGF Therapy for Diabetic Retinopathy in Chronic Kidney Disease.

Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China.

Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China.

Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis.

Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis.

Sterile Intraocular Inflammation Following Intravitreal Injections: Pathogenesis, Clinical Features, and Management.

Sterile Intraocular Inflammation Following Intravitreal Injections: Pathogenesis, Clinical Features, and Management.

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.

Comparison of ocular blood flow changes at 30 minutes after intravitreal injection of faricimab, brolucizumab, and aflibercept 2 mg for neovascular age-related macular degeneration.

Comparison of ocular blood flow changes at 30 minutes after intravitreal injection of faricimab, brolucizumab, and aflibercept 2 mg for neovascular age-related macular degeneration.